Disease-specific non–reducing end carbohydrate biomarkers for mucopolysaccharidoses
نویسندگان
چکیده
منابع مشابه
Disease-Specific Non-Reducing End Carbohydrate Biomarkers for Mucopolysaccharidoses
A considerable need exists for improved biomarkers for differential diagnosis, prognosis and monitoring of therapeutic interventions for mucopolysaccharidoses (MPS), inherited metabolic disorders that involve lysosomal storage of glycosaminoglycans. Here we report a simple, reliable method based on the detection of abundant nonreducing ends of the glycosaminoglycans that accumulate in cells, bl...
متن کاملCardiac Biomarkers in End-Stage Renal Disease
Patients with end-stage renal disease (ESRD) often suffer from cardiovascular complications and comorbidities. For example, 55% of ESRD patients suffer from congestive heart failure (CHF) and cardiovascular diseases account for the majority of deaths among ESRD patients (Herzog, Ma, & Collins, 1998; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases;...
متن کاملEffect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.
Endemic and epidemic shigellosis, an acute invasive disease of the lower intestines, afflicts millions of people worldwide with an estimated one million fatalities per annum at a low infectious dose. Our approach to vaccine development against Shigella is based on the hypothesis that serum IgG antibodies to the O-specific polysaccharide (O-SP) domains of the LPS of these organisms confer protec...
متن کاملEvaluation of disease severity in mucopolysaccharidoses.
The mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders characterized by a wide variation in symptoms and progression rates. Each of the MPS types is caused by a deficiency in one of the enzymes involved in the catabolic pathway of glycosaminoglycans. MPS are usually suspected on the basis of the concomitant presence of several typical features of the disease, such as short s...
متن کاملTherapy for the mucopolysaccharidoses.
Better understanding of disease pathophysiology, improved supportive care and availability of disease-specific treatments for some of the mucopolysaccharidosis (MPS) disorders have greatly improved the outlook for patients with MPS disorders. Optimal management of these multisystemic disorders involves a multidisciplinary team and regular, comprehensive follow-up. Enzyme replacement therapy (ER...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Chemical Biology
سال: 2012
ISSN: 1552-4450,1552-4469
DOI: 10.1038/nchembio.766